Literature DB >> 24131470

Regulating bioactivity of Cu2+ bis-1,10-phenanthroline artificial metallonucleases with sterically functionalized pendant carboxylates.

Andreea Prisecaru1, Vickie McKee, Orla Howe, Garret Rochford, Malachy McCann, John Colleran, Milan Pour, Niall Barron, Nicholas Gathergood, Andrew Kellett.   

Abstract

The synthetic chemical nuclease, [Cu(1,10-phenanthroline)2](2+), has stimulated research within metallonuclease development and in the area of cytotoxic metallodrug design. Our analysis reveals, however, that this agent is "promiscuous" as it binds both dsDNA and protein biomolecules, without specificity, and induces general toxicity to a diversity of cell lineages. Here, we describe the synthesis and characterization of small-molecule metallonucleases containing the redox-active cation, [Cu(RCOO)(1,10-phen)2](+), where 1,10-phen = 1,10-phenanthroline and R = -H, -CH3, -C2H5, -CH(CH3)2, and -C(CH3)3. The presence of coordinated carboxylate groups in the complex cation functions to enhance dsDNA recognition, reduce serum albumin binding, and offer control of toxicity toward human cancer cells, Gram positive and negative bacteria, and fungal pathogens. The induction of genomic dsDNA breaks (DSBs) were identified in ovarian adenocarcinoma cells using immunodetection of γ-H2AX. Formate, acetate, and pivalate functionalized complexes induced DSBs in a higher percentage of cells compared with [Cu(1,10-phen)2](2+), which supports the importance of inner-sphere modification toward enhancing targeted biological application.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24131470     DOI: 10.1021/jm401465m

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  8 in total

1.  The phosphate clamp: sequence selective nucleic acid binding profiles and conformational induction of endonuclease inhibition by cationic Triplatin complexes.

Authors:  Andreea Prisecaru; Zara Molphy; Ralph G Kipping; Erica J Peterson; Yun Qu; Andrew Kellett; Nicholas P Farrell
Journal:  Nucleic Acids Res       Date:  2014-11-20       Impact factor: 16.971

2.  C 3-symmetric opioid scaffolds are pH-responsive DNA condensation agents.

Authors:  Natasha McStay; Zara Molphy; Alan Coughlan; Attilio Cafolla; Vickie McKee; Nicholas Gathergood; Andrew Kellett
Journal:  Nucleic Acids Res       Date:  2016-11-28       Impact factor: 16.971

3.  Copper bis-Dipyridoquinoxaline Is a Potent DNA Intercalator that Induces Superoxide-Mediated Cleavage via the Minor Groove.

Authors:  Zara Molphy; Vickie McKee; Andrew Kellett
Journal:  Molecules       Date:  2019-11-26       Impact factor: 4.411

Review 4.  Copper(II) Phenanthroline-Based Complexes as Potential AntiCancer Drugs: A Walkthrough on the Mechanisms of Action.

Authors:  Sebastiano Masuri; Petr Vaňhara; Maria Grazia Cabiddu; Lukáš Moráň; Josef Havel; Enzo Cadoni; Tiziana Pivetta
Journal:  Molecules       Date:  2021-12-22       Impact factor: 4.411

5.  Mapping the DNA Damaging Effects of Polypyridyl Copper Complexes with DNA Electrochemical Biosensors.

Authors:  Anna Banasiak; Nicolò Zuin Fantoni; Andrew Kellett; John Colleran
Journal:  Molecules       Date:  2022-01-19       Impact factor: 4.411

6.  DNA oxidation profiles of copper phenanthrene chemical nucleases.

Authors:  Zara Molphy; Creina Slator; Chryssostomos Chatgilialoglu; Andrew Kellett
Journal:  Front Chem       Date:  2015-04-21       Impact factor: 5.221

7.  Synthesis of novel coumarin nucleus-based DPA drug-like molecular entity: In vitro DNA/Cu(II) binding, DNA cleavage and pro-oxidant mechanism for anticancer action.

Authors:  Saman Khan; Ali Mohammed Malla; Atif Zafar; Imrana Naseem
Journal:  PLoS One       Date:  2017-08-01       Impact factor: 3.240

8.  Di-copper metallodrugs promote NCI-60 chemotherapy via singlet oxygen and superoxide production with tandem TA/TA and AT/AT oligonucleotide discrimination.

Authors:  Creina Slator; Zara Molphy; Vickie McKee; Conor Long; Tom Brown; Andrew Kellett
Journal:  Nucleic Acids Res       Date:  2018-04-06       Impact factor: 16.971

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.